People: Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

10:34pm IST
Change (% chg)

$-0.05 (-1.20%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Riedel, Norbert 

Dr. Norbert G. Riedel is President, Chief Executive Officer, Director of the company. Dr. Riedel has served as a member of our board of directors and our President and Chief Executive Officer since June 2015. Dr. Riedel previously served as Chief Executive Officer and President of Naurex Inc., our predecessor company, from January 2014 to July 2015. From 2001 to January 2013, he served as Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, where from 1998 to 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017. Dr. Riedel also serves on the board of directors of Jazz Pharmaceuticals plc, Eton. Pharmaceuticals, Inc., Cerevel Therapeutics, LLC, and the Illinois Biotechnology Innovation Organization and is also a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University's Feinberg School of Medicine. Dr. Riedel previously served as an associate professor of medicine at Boston University School of Medicine and a visiting associate professor at the Massachusetts Institute of Technology. Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt. Dr. Riedel brings significant scientific, drug discovery and development, and commercial expertise to our board of directors with over 20 years of experience in the biotechnology and pharmaceutical industries.

Basic Compensation

Total Annual Compensation, USD 452,509
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,420,680
Fiscal Year Total, USD 1,873,190

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Wilbur Gantz


Norbert Riedel


Ashish Khanna


Andrew Kidd


Joseph Moskal


Patrick Enright

As Of  31 Dec 2018